PetVivo Secures Canadian Approval for Spryng, Launches AI Platform Amid Operational Update
PETV sits 47% above its 52-week low of $0.6 on elevated volume (2.7× avg).
Summary
PetVivo Holdings reported its fiscal 2026 operational results, notably securing Health Canada approval for its Spryng product, which expands its commercial opportunities. The company also launched the public beta of its AgenticPet AI platform, reporting over 1,000 active users and significant reductions in veterinary customer acquisition costs during its initial rollout. Additionally, PetVivo announced progress on Stage B of its R&D program with PiezoBioMembrane, following its recent acquisition. While the report detailed these positive operational advancements, it did not include specific financial results for the fiscal year. The commercial launch of Spryng in Canada is expected near the end of July, and the official commercial launch of the B2B AgenticPet AI platform is anticipated within the next few months.
At the time of this announcement, PETV was trading at $0.88 on OTC in the Life Sciences sector, with a market capitalization of approximately $31M. The 52-week trading range was $0.60 to $1.69. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.